Scott C F, Lambert J M, Goldmacher V S, Blatter W A, Sobel R, Schlossman S F, Benacerraf B
Int J Immunopharmacol. 1987;9(2):211-25. doi: 10.1016/0192-0561(87)90096-8.
We studied in mice the in vivo pharmacokinetics and toxicity of murine monoclonal antibodies (MCA) and of disulfide-linked MCA conjugates of gelonin, a ribosomal inhibitor prepared from the seeds of Gelonium multiflorum. Iodinated MCA with specificity for human determinants and of gamma 1 or gamma 2a isotype had a circulatory half life (T 1/2) in the mouse of 4 days, which is consistent with previously published estimates of the circulatory T 1/2 of heterogeneous murine IgG. Iodinated murine MCA with specificity for murine determinants had a much shorter T 1/2, probably reflecting antigen binding. This effect could be partially overcome by the simultaneous injection of unlabeled MCA of identical specificity. Clearance of MCA-gelonin conjugates was characterized by an initial rapid phase lasting 8-12 h with a T 1/2 or from 4 to 7 h, followed by a slower clearance phase with T 1/2 approaching that of MCA. Moreover, the presence of significant amounts of intact conjugate in the murine circulation was demonstrable, by SDS gel electrophoresis, for up to 48 h post injection. Intraperitoneal injection of MCA-gelonin conjugate resulted in circulating levels identical to those achieved after i.v. administration after an initial 4 h equilibration. The LD50 of MCA-gelonin conjugates was approximately 25 mg/kg (i.v.) while that of gelonin was approximately 75 mg/kg (i.v.) MCA alone showed no toxicity in doses in excess of 150 mg/kg. At doses below the LD50 immunoconjugates caused a dose-dependent reversible weight loss. The main site of toxicity of MCA-gelonin conjugates was the liver; histopathological examination revealed dose-dependent foci of necrosis and acute inflammation. No pathology was observed in lung, spleen, kidney, gut or brain. The relationship to previous work in this area is discussed.
我们在小鼠体内研究了鼠单克隆抗体(MCA)以及与去甲基金鸡纳(gelonin)通过二硫键连接的MCA缀合物的药代动力学和毒性,去甲基金鸡纳是一种从多花金鸡纳(Gelonium multiflorum)种子中提取的核糖体抑制剂。对人决定簇具有特异性且为γ1或γ2a同种型的碘化MCA在小鼠体内的循环半衰期(T 1/2)为4天,这与先前发表的关于异源鼠IgG循环T 1/2的估计值一致。对鼠决定簇具有特异性的碘化鼠MCA的T 1/2则短得多,这可能反映了抗原结合。同时注射相同特异性的未标记MCA可部分克服这种效应。MCA - 去甲基金鸡纳缀合物的清除特征为最初8 - 12小时的快速清除阶段,T 1/2为4至7小时,随后是清除较慢的阶段,T 1/2接近MCA的T 1/2。此外,通过SDS凝胶电泳可证明,在注射后长达48小时内,鼠循环中存在大量完整的缀合物。腹腔注射MCA - 去甲基金鸡纳缀合物后,经过最初4小时的平衡,其循环水平与静脉注射后达到的水平相同。MCA - 去甲基金鸡纳缀合物的半数致死剂量(LD50)约为25 mg/kg(静脉注射),而去甲基金鸡纳的LD50约为75 mg/kg(静脉注射)。单独的MCA在剂量超过150 mg/kg时未显示出毒性。在低于LD50的剂量下,免疫缀合物会导致剂量依赖性的可逆体重减轻。MCA - 去甲基金鸡纳缀合物的主要毒性部位是肝脏;组织病理学检查显示出剂量依赖性的坏死灶和急性炎症。在肺、脾、肾、肠道或大脑中未观察到病理学变化。本文还讨论了与该领域先前工作的关系。